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Heparanase attenuates axon 
degeneration following sciatic 
nerve transection
Michael J. Whitehead, Rhona McGonigal, Hugh J. Willison & Susan C. Barnett
Axon degeneration underlies many nervous system diseases; therefore understanding the regulatory 
signalling pathways is fundamental to identifying potential therapeutics. Previously, we demonstrated 
heparan sulphates (HS) as a potentially new target for promoting CNS repair. HS modulate cell 
signalling by both acting as cofactors in the formation of ligand-receptor complexes and in sequestering 
ligands in the extracellular matrix. The enzyme heparanase (Hpse) negatively regulates these processes 
by cleaving HS and releasing the attached proteins, thereby attenuating their ligand-receptor 
interaction. To explore a comparative role for HS in PNS axon injury/repair we data mined published 
microarrays from distal sciatic nerve injury. We identified Hpse as a previously unexplored candidate, 
being up-regulated following injury. We confirmed these results and demonstrated inhibition of Hpse 
led to an acceleration of axonal degeneration, accompanied by an increase in β-catenin. Inhibition of 
β-catenin and the addition of Heparinase I both attenuated axonal degeneration. Furthermore the 
inhibition of Hpse positively regulates transcription of genes associated with peripheral neuropathies 
and Schwann cell de-differentiation. Thus, we propose Hpse participates in the regulation of the 
Schwann cell injury response and axo-glia support, in part via the regulation of Schwann cell de-
differentiation and is a potential therapeutic that warrants further investigation.
Understanding the mechanisms underlying Wallerian degeneration in the peripheral nervous system (PNS) has 
progressed significantly since the discovery of the Wlds mouse1, which notably delays axonal degeneration in 
the distal stump after transection injury. Crossing the Wlds mice with various peripheral neuropathy models 
also leads to significant axonal protection2–4. The contribution of downstream pathways to axon degeneration 
are currently the subject of investigation, and include mitochondrial dysfunction, disruption of energy supply, 
calcium homeostasis and the activation of calpain proteases5–8. Schwann cells also play important roles in repair 
including phagocytosis of debris, promotion of regeneration via their secretome and ultimately, remyelination of 
regenerating axons9. There is no known direct causative link between Schwann cells and axon degeneration after 
injury, although it is becoming increasingly clear that Schwann cells provide metabolic support to axons and their 
disruption is associated with axonal degeneration10–12.
We have previously shown that heparin sulphate mimetics can modify certain characteristics of reactive astro-
cytosis13,14. Furthermore, treatment of dorsal root ganglion (DRG) cultures with heparin promotes PNS myelina-
tion in vitro via the specific inhibition of the soluble immunoglobulin (Ig)-containing isoforms of neuregulin 1 
(i.e., NRG1 types I and II), that negatively regulate myelination15. Herein we hypothesised that heparan sulphates 
(HS) could also modulate the PNS injury response. HS are linear glycosaminoglycan (GAG) chains attached 
to proteoglycans (HSPG). They are found in the extracellular matrix, attached to the extracellular leaflet of the 
plasma membrane. HS play an important role in the regulation of many cellular functions16,17 including facilita-
tion of the binding of proteins to their corresponding receptors, such as FGF and Wnt ligands18–21. HS mediated 
signalling is regulated by enzymes that cleave them, such as the endoglycosidase heparanase (Hpse), which release 
bound proteins22. Hpse acts both at the cell-surface and within the extracellular matrix to degrade polymeric hep-
aran sulfate molecules into shorter chain length oligosaccharides. Hpse is a prognostic marker for poor outcome 
in malignant tumours and its activity correlates with inflammatory acidosis23. Increased Hpse expression is also 
being increasingly implicated in diseases associated with neuroinflammation24. Whilst Hpse expression has been 
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identified in astrocytes and neurons of the CNS and has been shown to promote neurite extension in vitro25–27, 
there is currently, to the best of our knowledge, no association with Schwann cells or the PNS injury response.
In this study we have data mined previously published microarrays generated after sciatic nerve injury to 
identify genes associated with changes in HS. We identified the enzyme Hpse, known to degrade HS, as an mRNA 
upregulated after injury, in the distal stump. To investigate the biological relevance of Hpse activation following 
PNS injury we used two models: an ex vivo model of sciatic nerve injury and a nerve-muscle preparation which 
models distal motor nerve terminal injury. We identify an increase in Hpse after injury and accelerated axon loss 
plus myelin basic protein (MBP) loss correlating with Schwann cell de-differentiation following Hpse inhibition. 
This occurs at least in part due to Hpse’s ability to regulate β-catenin and subsequently Sox2 transcription.
Figure 1. Microarray, qPCR and protein analysis indicates a role for HS mediated signalling in Wallerian 
degeneration. (A) Heat map to show microarray analysis from two different published array sets obtained from 
GEO (refer to methods) for HSPG genes as well as genes associated with HS biosynthesis and regulation. Genes 
coloured yellow are not differentially expressed (DE) while genes with increasing expression become a gradually 
darker green, conversely genes that decrease in expression become gradually darker in orange and then red. The 
dendrogram, which illustrates clustering between genes, used a Euclidean measure to calculate distance and 
the complete agglomeration method for clustering, according to the heatmap.2 R package. Clustering of Ctsl, 
Hpse and Gpc1 is indicated by the box. Vertical bold line separates the profile from WT (left) and Wlds (right) 
mice. D = day. (B) RT-qPCR validation of selected highly expressed genes from the microarray results using 
an ex vivo SN injury model confirms Hpse is highly (significantly) up-regulated. All results compare uninjured 
SN to ex vivo SN after either 2 or 4 DIV. Hpse (2 DIV - *p = 0.03, n = 5, 4 DIV – **p = 0.0009, n = 6). Ctsl (2 
DIV - p = 0.2, n = 3, 4 DIV – p = 0.12, n = 3). GALNS (2 DIV – *p = 0.043, n = 3, 4 DIV – *p = 0.006, n = 6). 
E) Gpc1 (2 DIV - *p = 0.06, n = 4, 4 DIV – p = 0.22, n = 3) Gpc6 (2 DIV – *p = 0.04, n = 4, 4 DIV = p = 0.059 
n = 3). (C) Representative full Western blot from one experiment of, ex vivo SN, illustrates an upregulation 
in immunoreactivity for 3G10 antibody, that detects HS cleaved by Hpse, after 2 DIV (injured) compared to 
uninjured control – where no immunoreactivity was detected (n = 3). Amido black whole protein stain was 
used for loading control (refer to supplementary section Fig. S4). (D) Immunoreactivity/fluorescent staining 
for the antibody IOE4, which recognises a wide array of HS expression, demonstrates baseline presence of HS 
in the uninjured SN. Scale bar = 50 μM. (E) Immunostaining for Sox2 and DAPI in purified rat Schwann cells 
expressing endogenous GFP shows that (F) Hpse is expressed in purified rat Schwann cells using PCR (n = 2). 
Students T test or one sample T test was used for all statistical analysis.
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Figure 2. Heparanase inhibition accelerates acute axonal degeneration in ex vivo sciatic nerves. (A) 
Representative images of SMI31-IR (red) immunostaining of sections from ex vivo SN cultures either uninjured 
(naïve), after 2 DIV or 2 DIV treated with OGT2115, the Hpse inhibitor. In magnified images; MBP-IR 
(green) and DAPI-IR (blue). Quantification of SMI31-IR axons of images, *p = 0.02, n = 3. (B) Representative 
cropped Western blot from one experiment, for ex vivo SN, (representative full length blot is available in 
supplementary section Fig. S4) after OGT2115 treatment showing a significant decrease in SMI31 expression, 
quantified by densitometry, ***p = 0.0002, n = 3. Amido black whole protein stain was used for loading control 
(representative blot available in supplementary section Fig. S4). (C) Semi-thin sections of resin embedded ex 
vivo SN after 2 DIV or 2 DIV with OGT2115 treatment stained with methylene blue/azurII. Quantification 
of degenerating axons in the ex vivo SN after 2 DIV treated with OGT2115 showed a significant increase 
compared to 2 DIV alone, *p = 0.012, n = 4. Red arrow indicates a collapsed myelin sheath which represents 
a degenerating axon. (D) Representative Western blot of ex vivo SN after 2 DIV with or without OGT2115 
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Results
Hpse activity is consistently up-regulated after distal SN injury. To investigate a role for HS in the 
PNS we first analysed three previously published microarray (mRNA) data sets; two for distal SN injury and one 
for the DRG after SN injury. Figure 1A shows a heat map of the expression of HSPGs, as well as their biosynthetic 
and signal regulating enzymes derived from two microarray datasets. One comprised of data from transected 
SN from WT and Wlds mice at 3, 7 and 14 days (GSE22291) and the second comprised data from the DRG after 
injury (GSE58982). The Wlds mouse significantly delays axon degeneration after SN transection and is therefore 
a useful comparison to WT mice for identifying mechanisms associated with axon degeneration. In these datasets 
no significant difference in expression (DE) is observed for HSPGs, except for glypican-1 (Gpc1) and glypican-6 
(Gpc6). Upregulation of Hpse was seen after WT injury at all time points, and its gradual down-regulation was 
observed following injury in in Wlds compared to WT (Fig. 1A). A further published microarray for the injured 
distal SN also showed upregulation of Hpse (7 days after injury; GSE38693)28. Cathepsin–L (Ctsl), which acti-
vates Hpse enzymatic activity29, showed a similar expression profile to Hpse and the cluster analysis groups Hpse, 
Ctsl and Gpc-1 together (Fig. 1A). Galactosamine (N-acetyl)-6-Sulfatase (GALNS), which is up-regulated after 
WT injury and comparatively decreased in Wlds injury, also removes 6-O sulphate groups30. To verify the pub-
lished microarray results we first used an ex vivo model of SN injury31. The advantages of using this model over 
whole animal in vivo SN injury include the ability to isolate the SN from the infiltrating immune system, ease of 
inhibitor administration and reduced animal suffering. RT-qPCR after 2 and 4 DIV confirmed Hpse (3/15 fold, 
p = 0.03/0.0009) and GALNS (5/4.67 fold, p = 0.043/0.006) were significantly up-regulated compared to unin-
jured control (Fig. 1B). Changes in Ctsl, Gpc1 and Gpc6 were not statistically significant after injury; however 
there was a trend towards an increase in expression (Fig. 1B).
To demonstrate an increase in Hpse activity after SN injury we used the antibody 3G10, which binds to HS 
stubs cleaved by Hpse, thereby acting as indirect evidence for heparanase activity. Western blot analysis of the 
ex vivo SN confirmed an increase in 3G10 antibody binding after 2 DIV, when compared to the uninjured SN 
(Fig. 1C). Figure 1D shows immunoreactivity (IR) for the antibody 10EA, which binds most HS, in the uninjured 
SN. This illustrates the presence of HS both axonally, and on the abaxonal layer of the myelin sheath (Fig. 1C). 
As Schwann cells are the predominant cell type in the SN we investigated whether Schwann cells express Hpse 
by PCR. Using purified cultures of Schwann cells we detected a band at the expected size for Hpse (Fig. 1E,F), 
suggesting that in the ex vivo sciatic nerve tissue, Hpse is expressed at least by Schwann cells.
Hpse protects against acute axonal loss in the ex vivo sciatic nerve. In order to determine the role 
of Hpse in distal SN degeneration we treated the ex vivo SN with the Hpse inhibitor OGT2115. Quantification of 
SMI31-IR positive axons in nerve sections showed a 40% acceleration of axon loss with OGT2115 treatment, after 
2 DIV (Fig. 2A, p = 0.02). We selected 2 DIV since after peripheral nerve injury it has been reported that there is 
an additional latency phase before axon degeneration takes place, which is marked at approximately 36–40 hrs in 
mouse ex vivo sciatic nerve injury10. Western blot analysis of the tissue (Fig. 2B) also showed a 90% (p = 0.0002) 
decrease in SMI31 protein levels after 2 DIV with OGT2115 treatment. Consistent with this, quantification of 
degenerating axons revealed a two fold increase after OGT2115 treatment compared to 2 DIV alone (Fig. 2C) 
(p = 0.012). The 3G10 anti-HS stub antibody was then used to assess whether OGT2115 was inhibiting Hpse. 
Western blot analysis of the tissue (Fig. 2C) reveals a 78% reduction in 3G10 binding (p = 0.008). Addition of 
heparinase I (a substitute for Hpse)32 caused a 70% attenuation of the loss of SMI31 protein levels in the ex vivo 
SN after 2 DIV as indicated by Western blot (Fig. 2E, p = 0.026). It was not possible to test heparinase I treatment 
on axonal degeneration ex vivo as experiments suggest the enzyme was not able to sufficiently penetrate the tissue 
(data not shown). Alamar blue, a redox indicator that yields a colorimetric change and a fluorescent signal in 
response to metabolic activity was used to confirm that OGT2115 treatment was not cytotoxic. No difference in 
signal after alamar blue treatment was found in the ex vivo SN with OGT2115 treatment, compared to control, 
until 2 DIV at which point there was a significant increase in metabolic activity due to the reduction of alamar 
blue (Fig. 2F).
Hpse inhibition promotes NMJ injury, in an ex vivo distal motor nerve injury model. To further 
support a role for Hpse activity in enhancing distal peripheral nerve axon survival following axotomy, we used 
an ex vivo nerve muscle preparation from the triangularis sterni (TS) muscle. In this preparation, terminal axons 
can be seen to project into the neuromuscular junction (NMJ) and be observed to degenerate following proximal 
axonal injury. Staining allows us to quantify injury as end plate occupancy as defined in the methods. After 24 hrs 
the ratio of occupied endplates decreased by 70% after OGT2115 treatment, compared with a decrease of 28% in 
showing a significant decrease in HS (3G10) cleaved by Hpse **p = 0.008, n = 3. (E) Representative cropped 
Western blot from one experiment, of ex vivo SN, (representative full length blot is available in supplementary 
section Fig. S4) after 2 DIV with or without Heparinase I treatment showing a significant decrease in the 
loss of SMI31 protein levels *p = 0.026, n = 3. Amido black whole protein stain was used for loading control 
(representative blot available in supplementary section Fig. S4). (F) Alamar blue analysis for cell viability of 
ex vivo SN treated with OGT2115. It can be seen that there was no difference in levels between OGT2115 
treatment and control (not shown) until 2 DIV where a significant increase was observed after OGT2115 
treatment, *p = 0.018. n = 3. The data from the alamar blue assay was normalised to results obtained from 
cultured media lacking cells containing the alamar blue only, which is defined as the negative control. Students 
T test was used for all statistical analysis or one-way ANOVA with post hoc Tukey HSD test.
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controls (Fig. 3, p = 0.025). This 24 hr time point was the earliest at which changes in the NMJ or signs of injury 
were seen.
Hpse down-regulates β-catenin and β-catenin inhibition protects against axonal loss. HS are 
known to facilitate Wnt receptor binding19, prompting us to analyse Wnt signalling pathways in SN injury, using 
the same previously published microarrays. Figure 4A shows a heat map for Wnt ligands, receptors and Wnt 
signalling regulators. This shows a decrease in expression of Rspo1, Frzb, Fzd3 and Wnt5 and an increase in the 
expression of Wif1 and Wnt2 (Fig. 4A) in WT injury. When comparing WT injury to Wlds there is a significant 
decrease in Wif1 and increase in Rspo1 at later time points. Wif1 and Rspo1 are potent regulators of Wnt sig-
nalling and are also the most highly differentially expressed (DE) in the published microarrays. Prompting us to 
validate their differential expression using RT-qPCR in the SN injury model. However while this downregulation 
was confirmed for Rspo1 (2 DIV – p = 0.089, n = 3, 4 DIV - **p = 0.003, n = 3), Wif1 was also unexpectedly 
down-regulated (2 DIV p = 0.005, 4 DIV p = 0.0076) (Fig. 4B,C) compared to uninjured control, indicating a 
discordance with the microarray analysis.
As an alternative pathway to verify the inhibition of Wnt signalling we next investigated β-catenin, a down-
stream component of canonical Wnt signalling, by measuring β-catenin protein levels under injured and Hpse 
inhibitor conditions in the ex vivo SN. When comparing uninjured nerves to 2 DIV there was a significant 
decrease in both β-catenin (Fig. 3B, p = 0.03) and active β-catenin (Fig. 3B, p = 0.004). However after OGT2115 
treatment there is a significant two fold increase in β-catenin, compared to 2 DIV alone (Fig. 5C, p = 0.009). 
β-catenin was then inhibited with XAV939. Quantification of SMI31-IR axons in sections after XAV939 treat-
ment, showed a significant 36% protection of SMI-31-IR axons (Fig. 5D, p = 0.03). Western blot analysis also 
showed a significant protection of SMI31 protein levels after XAV939 treatment (Fig. 5D).
Bioinformatics identified β-catenin transcription targets associated with nerve injury response. 
To further understand signalling induced by the SN injury response we next conducted a more unbiased approach 
for identifying genes potentially involved in the Schwann cell injury response, again by interrogating published 
microarrays. A gene was selected if it was differentially expressed only in WT mouse SN injury and not in the 
Wlds mouse or the DRG after injury (Supplementary Fig. 1). This procedure identified 131 genes, which were 
then narrowed down to 71 genes by looking at the earliest time point (3 days) to try and identify initial molecu-
lar mechanisms. Within this list, genes associated with peripheral neuropathies were enriched. Although these 
genes were present in the original differentially expressed gene list, their identity was emphasised by this process 
(Annokey, a high throughput Pubmed search)33. Out of these 71 genes, 10 (10/71 genes) are associated with 
peripheral neuropathies compared to all DE genes (3 days after injury) which have 15 (15/1766 genes).
Furthermore, of these 71 genes, 21 are predicted to be positively transcriptionally regulated by LEF1 and 
TCF3, which are part of the β-catenin signalling pathway34 (Supplementary Fig. 2). In conclusion, we show that 
Figure 3. Hpse inhibition promotes loss of innervated NMJ, in an ex vivo distal motor nerve injury model. (A) 
Untreated triangularis sterni preparation at 24 h shows normal distal nerve terminal innervation (SMI31-IR 
(red), CFP expression (cyan) in axons innervating nerve terminals, indicated by ά – bungarotoxin-IR (green). 
Red arrow indicated end plates. Blue arrow indicates CFP positive intramuscular nerve bundles. (B) OGT2115 
treated TS preparation shows loss of SMI31-IR (red) and CFP expression (cyan) in axons innervating nerve 
terminals, indicated by α – bungarotoxin-IR (green). (C) Quantification of % SMI31-IR end plate occupancy 
shows a loss of SMI31-IR end plate occupancy after OGT2115 treatment, *p = 0.025, n = 3.
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β-catenin, which can be negatively regulated by Hpse activity, is predicted to transcriptionally up-regulate 21 
genes hypothesised to play a role in SN injury using an unbiased microarray screen.
To validate the DE genes of these 21 genes we carried out RT-qPCR of the ex vivo SN for 6 selected genes. 
Nrcam, Gjb1 and Sox2 were significantly DE after injury while Cdh1, Drp2 and Nr4a2 were not statistically DE 
(Supplementary Fig. 3). These genes were then investigated after Hpse inhibition following which Gjb1 (p = 0.02), 
Drp2 (p = 0.003), Nrcam (p = 00016), Sox2 (p = 0.011), Nr4a2 (p = 0.004) but not Cdh1 (p = 0.06) were sig-
nificantly DE (Fig. 6A). Sox2 showed the largest differential expression after OGT2115 treatment. As Sox2 has 
been previously shown to promote Schwann cell de-differentiation35,36 we hypothesised that the increase in Sox2 
mRNA after Hpse inhibition is acting to promote Schwann cell de-differentiation. In support of this dediffer-
entiation hypothesis we observed a gradual decline in MBP expression on Western blot with Hpse inhibition 
(Fig. 6B,C, 2 DIV p = 0.3, 4 DIV p = 0.003).
Discussion
Whilst extensive research into the mechanisms of axonal degeneration has been conducted, the molecular path-
ways involved remain unclarified with no specific therapeutics identified. Here we highlight a role for HS in mod-
ulating peripheral axon degeneration following injury and identify the regulation of HS signalling as an important 
pathway for protecting peripheral nerve axon degeneration. HS have the ability to regulate multiple signalling 
pathways16 and whilst they have been identified as effective therapeutic targets in several diseases, including can-
cer37, Alzheimer’s disease38 and diabetes39, their role in peripheral nerve injury has not been explored. We have 
identified Hpse, the enzyme that modulates HS signalling, as a protector of axon degeneration. Our data indicates 
that Hpse is protective, and Hpse inhibition accentuates axon degeneration as a consequence of β-catenin signal-
ling and Schwann cell de-differentiation.
Our findings demonstrating that Hpse attenuates axon degeneration in the ex vivo SN explant model is the 
first functionally relevant report of Hpse activity in the PNS. Whilst glia in the CNS have been shown to express 
Hpse26,40, this is the first study to identify its expression in Schwann cells. Hpse has previously been shown to 
protect against axon degeneration in Alzheimer’s disease models, where it inhibits HS mediated amyloid-β 
Figure 4. Bioinformatics of DE Wnt signalling components in the distal sciatic nerve after injury shows 
a decrease in Wnt signalling. (A) Heatmap for numerous components of the Wnt signalling pathway. The 
legend shows that genes not DE are yellow while those that increase in expression become gradually more 
green and those that decrease in expression becoming gradually more orange and then red. The dendrogram, 
which illustrates clustering between genes, used a Euclidean measure to calculate distance and the complete 
agglomeration method for clustering. Wif1 was strongly up-regulated while Rspo1 was down-regulated. 
D = days. (B) RT-qPCR for Rspo1 after 2 and 4 DIV from the ex vivo SN shows a significant decrease after 4 
DIV (2 DIV – p = 0.089, n = 3, 4 DIV - **p = 0.003, n = 3). (C) RT-qPCR for Wif1 after 2 and 4 DIV from the 
ex vivo SN showing the opposite from bioinformatics data (2 DIV – **p = 0.005, n = 3, 4 DIV - **p = 0.0076, 
n = 3). One sample T test was used for all statistical analysis.
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deposition41. The only known role for Hpse2 (an in-active splice variant of Hpse) specifically in the PNS is in 
the development of urofacial syndrome, where Hpse2 knock-out perturbs the correct development of motor 
neurones via fibroblast growth factor (FGF) mediated gene transcription42. Hpse has also been shown to promote 
neurite out growth via regulation of nerve growth factor (NGF) signalling25 and HS plays an important role in 
axon guidance43. Hpse activity also modulates neuroinflammatory effects on macrophage activation (via c-fos 
induced cytokine expression)44, the recruitment of immune cells to the site of injury (via remodelling of the extra-
cellular matrix)45, and autophagy46. Whether Hpse affects the immune response after peripheral nerve injury, as 
Figure 5. Hpse inhibition in ex vivo sciatic nerves increases β-catenin protein levels and β-catenin inhibition 
protects against SMI31 loss. (A) Representative cropped Western blot from one experiment for β-catenin 2 
DIV after injury compared to uninjured ex vivo SN, showing a significant decrease in β-catenin after injury 
(n = 5, *p = 0.03). (B) Representative cropped Western blot from one experiment for active β-catenin in ex vivo 
SN either uninjured or after 2 DIV. Quantification shows a significant decrease in active β-catenin after injury 
(n = 3, **p = 0.004). (C) Representative cropped Western blot from one experiment for β-catenin in ex vivo 
SN either 2 DIV or 2 DIV with OGT2115 treatment shows a significant increase in β-catenin with OGT2115 
treatment (n = 4, **p = 0.009). (D) There is a significant protection of SMI31-IR axons and protein levels after 
2 DIV with β-catenin inhibition (XAV939 treatment). Images of ex vivo SN sections immunolabelled with 
SMI31 (red) showing axons after 2 DIV with or without XAV939 treatment (n = 3, *p = 0.03). Representative 
cropped SMI31 Western blot from one experiment for ex vivo SN after 2 DIV with or without XAV939 shows 
protection of SMI31 after XAV939 treatment (n = 3). For all Western blots shown in (A–D), the full length 
blots are available in supplementary section (Fig. S4). In all cases amido black whole protein stain was used as a 
loading control, representative blots are available in supplementary section (Fig. S4). Student T test was used for 
all statistical analysis.
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well as its role during regeneration of the proximal stump, has not been investigated herein. In the SN, HS are 
expressed on the abaxonal myelin sheath and we show that their remodelling via the up-regulation of Hpse after 
injury inhibits β-catenin signalling (Fig. 7). As such inhibiting Hpse, which accelerates axon degeneration, also 
promotes β-catenin signalling.
The link between β-catenin and axonal degeneration in the ex vivo SN explant model is previously uniden-
tified. β-catenin has also been shown to promote axon loss in a PD model and conversely to protect against 
axon degeneration in AD models46,47. Whilst the mechanisms behind its negative role in PD are unclear, in AD 
it regulates mitochondrial damage by closing the mitochondrial permeability transition pore (mPTP)47, which 
has also been shown to play a fundamental role in SN injury48. Canonical Wnt signalling is a ubiquitous and 
important pathway in many systems. In Schwann cells, β-catenin is a fundamental regulator of development and 
subsequent radial sorting49. β-catenin has also been shown to promote Schwann cell myelination by activating the 
Figure 6. Heparanase regulates Schwann cell de-differentiation markers. (A) RT-qPCR for ex vivo SN 
comparing 2 DIV to 2 DIV + OGT2115. Gjb1 (p = 0.02, n = 6), Drp2 (0.003, n = 5), Nrcam (p = 0.016, n = 5), 
Sox2 (p = 0.011, n = 4), Nr4a2 (p = 0.004, n = 5), Cdh1 (p = 0.6, n = 7). Line refers to 1 i.e. no difference 
between control and treatment. (B) Representative Western blot for MBP in the ex vivo SN after 2 DIV 
compared to 2 DIV + OGT2115. Quantification shows no significant difference to control (p = 0.33, n = 3). 
(C) Representative Western blot for MBP in the ex vivo SN after 4 DIV compared to 4 DIV + OGT2115. 
Quantification shows a significant decrease in MBP after OGT2115 treatment (p = 0.003, n = 3). For all Western 
blots shown in (B–C), the full length blots are available in supplementary section Fig. S4. In all cases amido 
black whole protein stain was used as a loading control, representative blots are available in supplementary 
section Fig. S4. Students T test or one sample T test was used for all statistical analysis.
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transcription of myelin proteins50. Microarray analysis has implicated Wnt signalling in SN injury previously51, 
but was not subsequently explored. From the current data we hypothesise a role for β-catenin in injury induced 
de-differentiation of Schwann cells.
We also hypothesise that Hpse inhibition promotes Schwann cell de-differentiation mediated by a β-catenin/
Sox2 axis. β-catenin has previously been shown to up-regulate the transcription of Sox2 in other contexts52. It is 
known that Sox2 plays an important role in inhibiting Schwann cell myelination and promoting de-differentiation 
and proliferation35,36. Moreover, Schwann cells de-differentiate after injury into a more immature progenitor like 
state9. Here we show that Hpse inhibition increases Sox2 transcription, which in turn promotes Schwann cell 
de-differentiation. Myelinating Schwann cells are tightly coupled to axons and provide metabolites, the disruption 
of which, specifically in Schwann cells, can cause age dependent axon degeneratio10,12. We therefore hypothesise 
that Schwann cell de-differentiation disrupts this axo-glia symbiosis, which in turn accelerates axon degeneration; 
as has been hypothesised recently53. However it is also plausible that heparanase acts by releasing growth factors 
from the extracellular matrix (ECM)37, several of which have been implicated as therapeutics in peripheral neu-
ropathies54; including nerve growth factor (NGF), which protected small fibre degeneration in a diabetic mouse 
model55. Thus, Hpse mode of action may have several mechanisms of action including via β-catenin signalling, 
and potentially also via the release of growth factors. Hpse is already a therapeutic target in other diseases, and we 
highlight a new application following peripheral nerve injury mediated via inhibiting a β-catenin/Sox2 signalling 
axis, that in turn attenuates Schwann cell de-differentiation and axon degeneration.
Methods
Bioinformatics. Previously published microarrays were accessed from NCBI’s gene expression omnibus 
(GEO) microarray depository: GSE22291, GSE38693, and GSE5898228,56,57.
Microarrays were analysed using GEO2R, the affiliated tool for the GEO depository that uses the Bioconductor 
packages in R58. Heat maps were generated using the heatmaps2 function in ggplot for R. Volcano plots were gen-
erated using the standard plot function in R. Annokey online was run using python version 2.7.12 via the macOS 
terminal33. Enriched transcription factor prediction was performed using the molecular signatures database59. 
The dplyr package in R was used to filter and sort microarray results. R version 3.3.2 using the integrated devel-
opment environment (IDE) RStudio. DE genes are those with a log2fc <1.5 or log2fc <−1.5 and an adjusted 
p value < 0.05. For the unbiased identification of genes potentially important in sciatic nerve injury they were 
Figure 7. Hypothesis for the regulation of β-catenin by Hpse, in Schwann cells. The square indicates the region 
of the Schwann cell body and the abaxonal myelin sheath layers magnified in the lower schematics. When Hpse 
is up-regulated (after injury) the enzyme cleaves HS which decreases the likelihood of Wnt ligands binding 
to their receptor. This absence in signal results in the proteosomal degradation of β-catenin. When Hpse is 
inhibited by OGT2115 (during injury) the likelihood of the Wnt ligands binding to their receptor increases 
which stabilises β-catenin. β-catenin is then able to enter the nucleus and transcribe genes such as Sox2 which 
will promote SC de-differentiation and, we hypothesise, promote axon degeneration.
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selected if DE in WT injury and equally and oppositely expressed in Wlds injury compared to WT. This strict cut 
off was used instead of simply selecting genes DE in WT and not DE expressed in Wlds in an attempt to reduce 
the number of potential candidates.
Animals and ethical considerations. Adult Sprague Dawley (SD) rats from Harlan laboratories were used 
for ex vivo sciatic nerve explants. For triangularis sterni (TS) neuromuscular preparations, homozygous and het-
erozygous (F1) double-fluorescent adult B6.Cg-Tg(Thy1-CFP/S100B-GFP) mice, which express intracytosolic 
CFP in their peripheral motor and sensory axons and intracytosolic GFP in their Schwann cells were used as 
previously described60. All experiments were performed in accordance with a licence approved and granted by 
the United Kingdom Home Office and conformed to University of Glasgow institutional guidelines. Procedures 
complied with relevant guidelines outlined in the revised Animals (Scientific Procedures) Act 1986.
Ex vivo explant cultures of sciatic nerve degeneration and triangularis sterni preparations. The 
ex vivo sciatic nerve degeneration assay was conducted as previously described48. Briefly both sciatic nerves were 
dissected from adult SD rats and cut into four equal segments. The segments were cultured in 24 well plates with 
500 µl of Neurobasal media (ThermoFisher Scientific) supplemented with B27 (ThermoFisher Scientific), for the 
indicated number of days. Triangularis sterni (TS) muscles were dissected from the rib cage of B6.Cg-Tg mice 
pinned out flat as previously described61 and maintained in Ringers solution at 4 °C for 19 hrs. The Hpse inhibitor 
OGT2115 (Tocris Bioscience) was used at 8 μM62. There is believed to be only one enzymatically active Hpse in 
mammals, and OGT2115 is the only commercially available inhibitor, its precise mechanism of action is not 
known. XAV939 the β-catenin inhibitor was used (Tocris Biosciences) at 40 μM63. Both inhibitors were dissolved 
in DMSO and all controls were treated with DMSO only. Inhibitors were immediately added to the excised sciatic 
nerves or TS muscle.
Purified Schwann cells. Schwann cells were harvested and purified according to O’Neill et al.13, modified 
from Raff et al.64. Briefly Schwann cells were purified from P7 sciatic nerves of F344‐Tg(UBC‐EGFP)F455Rrrc 
(RRRC, Rat Resource and Research Centre) and cultured in DMEM with 5% FBS and supplemented with 0.5 μM 
forskolin (Sigma-Aldrich) and 50 nl/ml heregulin β1 (R&D Systems). Schwann cells were purified using an 
immunomagnetic positive selection kit (EasySep, Stem Cell Technologies), with the antibody p75NTR (Abcam).
Immunofluorescence and histology. Ex vivo SN tissue was fixed in 4% paraformaldehyde (1xPBS, pH 
7.4) for 1 hr, washed in PBS and placed in 30% sucrose solution for 1hr. The nerve segment was then cut in half 
with a razor blade and frozen in OCT (Tissue-TEK) and transverse sections cut with a cryostat. For each exper-
iment one nerve was used as control and the other for treatment. Two contralateral segments from each sciatic 
nerve were used per condition. Each nerve segment was cut into 9 sections with a 100 μM gap between each three. 
Tissue was permeabilised for internal antigens using ethanol at −20 °C for 20 min, prior to primary antibody(s) 
incubation o/n at 4 °C. After washing the secondary antibody was incubated for 1 hr at room temp (RT) washed 
again and mounted in Vectashield (Vector Labaratories). The number of axons per region of interest was man-
ually counted in Fiji using the cell counter plugin with SMI31 staining, for a set area of interest (40.4mm2). All 
exposure settings on a Leica DFC350 FX microscope were kept constant between images.
Immunocytochemistry for the NMJ ex vivo preparation was performed similarly to the ex vivo sciatic carried 
out by counting whether 100 NMJ (identified by post-synaptic α-bungarotoxin that binds nAChR positivity) 
were innervated by SMI3I positive axons or not (which we define as end plate occupancy). Histology of sciatic 
nerve explants was performed by first perfusing the tissue with 5% glutaldehyde/4% PFA before resin embedding 
according to65. Semi-thin sections were stained with methylene blue/azurII and degenerating axons were counted 
as previously.
Gene Forward primer Reverse primer
Hpse CAATGATAT TTGCGGGTCTG TGCGTT TTGGAA AGCTGACT
CtsL AATGGGGAGTACAGCAACGG TCCTCATTGGTCATGTCACCG
Galns GCTCATGGACGATATGGGGT TGTGTAGAAGCCATTGCGGA
Gpc1 GTATCGATGACCACTTCCAGC AGAGACGCAGCTCAGCATAC
Gpc6 ATGCAGCACAGTGTCACAGA TGTGTCCATTCCAGCACTCC
Wif1 AAAGCAAGTCTGTCTGCGAG CGACACTGGCATTTGTTGGG
Rspo1 GCAGTCCTGCACAATGTGAAAT ATCCCTTCCGGAAACCACAC
Cdh1 TTCAACCCAAGCACGTACCA TGTACACAGCATTCCACGCT
Drp2 CGACTGCAGTGAGACACCT TGCTCAATTCGAGAGTGTGTG
Gjb1 CTTGCTCAGTGGCGTGAATC ATGACGGACAGCCATACTCG
Nr4a2 GGTTTCTTTAAGCGCACGGT TAAACTGTCCGTGCGAACCA
Nrcam CGCTCTGGATGTTCCTCTTGA GTCCAGGAAAAGCTTGGAGGA
Sox2 CTCTGTGGTCAAGTCCGAGG ATGCTGATCATGTCCCGGAG
Ankrd27 TGCAGAGCAGGACTCAAAGAT GCAGGTTGTACATTTTGGGGTT
Table 1. Primers for RT-PCR.
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RT-qPCR. TRIzol (Invitrogen) was used to extract RNA with a purelink micro RNA extraction kit (Abcam). 
Quantitech reverse transcriptase kit (Qiagen) was then used to make cDNA from the RNA. cDNA was amplified 
using Quantifast Sybr green (Qiagen) and quantified using the 7500 fast real-time PCR machine. Fold changes 
were calculated using the ΔΔct method. Primers were designed using the pick primers function for NCBI and 
made by integrated DNA technologies (IDT). Housekeeping primers were used and made according to66. Table 1 
illustrates primers used for RT-PCR.
Western blot. Sciatic nerve segments were lysed and homogenised in Cell Lytic MT lysis buffer with protease 
inhibitor cocktail (Sigma-Aldrich). Protein samples (20 μg) were treated with reducing agent and sample buffer 
(Invitrogen) before 10 min incubation at 90 °C. Once cooled samples were run on SDS-PAGE gels (Invitrogen, 
NuPAGE 4–15% Bis-Tris gel) and transferred to nitrocellulose using an iblot (Invitrogen). The Western blot was 
performed using standard techniques, visualised and captured using the Azure C500 (Azure Biosystems) and 
densitometry analysis was performed using Fiji. Whole protein was used as a loading control with the amido 
black stain (Sigma) where densitometry analysis for each entire lane was used to normalise in Fiji, after being 
captured using the AzureC500 (Azure Biosystems)67.
Primary/Secondary antibodies. The following antibodies were used for immunofluorescence (IF) and/
or Western blot analysis: SMI31 – 1:1000 for WB and IF (Millipore, NE1022). MBP – 1:500 for WB and IF 
(Millipore, MAB382). β-catenin WB 1:500 (BD Biosciences, 610153). Active β-catenin (clone 8E7) (Millipore). 
α-bungarotoxin (Btx: to visualise NMJ, Invitrogen). F69-3G10 – 1:500 for WB (referred to as 3G10 in results) 
(Amsbio). F58-10E4 – 1:100 for IF (referred to as 10EA in results)(Amsbio). Sox2 – 1:1000 for Western blot 
(Abcam). WB secondary: Mouse IgG HRP-linked (GE Healthcare, NXA931). IF secondary: Alexa Fluor mouse 
IgG1, IgG2a (ThermoFischer Scientific, A-21121).
Statistics. An unpaired Student’s T test was performed for statistical analysis when comparing two conditions 
and a one-sample T test was used for RT-qPCR analysis. For multiple comparisons a one-way ANNOVA with 
Tukey honestly significant difference (HSD) post hoc test was performed. p < 0.05 and a confidence interval that 
did not cross 0 was considered statistically significant. For immunohistochemical analysis and Western blots of 
tissue n = 3–4 were performed. For RT-qPCR n = 3–6 were performed. These n numbers were based on previous 
experience with these methods in the laboratory.
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